Wondering whether your idea may become a viable product/service? Why should you care about market analysis and competitive landscape? Where to find market information relevant to your idea?
In this SPARK Europe Webinar, Andrij Włach will show you how to approach the market analysis in an efficient manner without losing your mind. Andrij Włach is an expert in business planning and evaluation of investment projects. He has gained his experience, among others, as a financial advisor at Wroclaw Research Center EIT+ and authorized adviser in the New Connect Stock Exchange Market. Former member of supervisory boards in many startups (BOSSG & EIT+ Technologies, Incuvo, Infermedica, Ekoinwentyka, Hybrid Glass Poland, Startit Vet). Since 2014 Andrij has held the role of a partner in Kvarko Group, managing the Group‘s finances, conducting intellectual property valuations, and supporting the development of startups in the company’s portfolio. Kvarko Group, as an investment fund supports currently more than 20 companies from the high-tech and life science industry.
Online via Zoom ǀ Please register here!
Please note that you will receive the access link the evening before the lecture and that access to last minute registrations, cannot be guaranteed.
The webinar will be hosted by SPARK Poland.
SPARK Europe is the joint network of SPARK sites all over Europe including Israel: SPARK-BIH, SPARK Finland, SPARK FLI, SPARK Poland and SPARK Tel Aviv. European SPARK programs are members of SPARK Global network. The purpose of SPARK programs is to provide the education and mentorship necessary to advance research discoveries from the bench to the bedside, hence to increase the maturity of academic and clinical discoveries towards practical solutions that address unmet needs in the life science and health tech space. The program follows the same principles that have been the cornerstones of SPARK at Stanford since it was established by Professor Daria Mochly-Rosen and Kevin Grimes in 2006 for advancing new biomedical research discoveries into promising new treatments for patients.
